Information Provided By: 
Fly News Breaks for February 12, 2018
LJPC
Feb 12, 2018 | 05:13 EDT
Jefferies analyst Eun Yang double downgraded La Jolla Pharmaceutical to Underperform from Buy and cut her price target for the shares to $29 from $40. The analyst says her critical care physician and Pharmacy & Therapeutics committee member polls on Giapreza point to a "likely modest" sales opportunity relative to consensus expectations. In the absence of a potential buyout, downside risks in the stock are greater relative to upside potential in the next two-to-three years, Yang tells investors in a research note.
News For LJPC From the Last 2 Days
There are no results for your query LJPC
